PL3122878T3 - TERAPIA mRNA DO LECZENIA CHORÓB OCZU - Google Patents
TERAPIA mRNA DO LECZENIA CHORÓB OCZUInfo
- Publication number
- PL3122878T3 PL3122878T3 PL15767977T PL15767977T PL3122878T3 PL 3122878 T3 PL3122878 T3 PL 3122878T3 PL 15767977 T PL15767977 T PL 15767977T PL 15767977 T PL15767977 T PL 15767977T PL 3122878 T3 PL3122878 T3 PL 3122878T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- ocular diseases
- mrna therapy
- mrna
- therapy
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969483P | 2014-03-24 | 2014-03-24 | |
| PCT/US2015/021403 WO2015148247A1 (en) | 2014-03-24 | 2015-03-19 | Mrna therapy for the treatment of ocular diseases |
| EP15767977.0A EP3122878B1 (en) | 2014-03-24 | 2015-03-19 | Mrna therapy for the treatment of ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3122878T3 true PL3122878T3 (pl) | 2019-06-28 |
Family
ID=54196241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15767977T PL3122878T3 (pl) | 2014-03-24 | 2015-03-19 | TERAPIA mRNA DO LECZENIA CHORÓB OCZU |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170143848A1 (pl) |
| EP (3) | EP3699274A1 (pl) |
| CY (1) | CY1121348T1 (pl) |
| DK (2) | DK3450553T3 (pl) |
| ES (2) | ES2774552T3 (pl) |
| HR (1) | HRP20190117T1 (pl) |
| HU (1) | HUE041940T2 (pl) |
| LT (1) | LT3122878T (pl) |
| ME (1) | ME03314B (pl) |
| PL (1) | PL3122878T3 (pl) |
| PT (1) | PT3122878T (pl) |
| RS (1) | RS58337B1 (pl) |
| SI (1) | SI3122878T1 (pl) |
| SM (1) | SMT201900176T1 (pl) |
| TR (1) | TR201900649T4 (pl) |
| WO (1) | WO2015148247A1 (pl) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58405B1 (sr) | 2009-12-01 | 2019-04-30 | Translate Bio Inc | Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima |
| CA3198966A1 (en) | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Cleavable lipids |
| JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
| US20150166985A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting von willebrand factor point mutations |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA2956224A1 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and uses thereof |
| AU2016366978B2 (en) | 2015-12-10 | 2022-07-28 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| WO2017180917A2 (en) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
| SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| EP3544591B1 (en) | 2016-11-23 | 2022-04-20 | Mayo Foundation for Medical Education and Research | Particle-mediated delivery of biologics |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| AU2018224843B2 (en) | 2017-02-27 | 2024-08-15 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| HUE059594T2 (hu) | 2017-02-27 | 2022-11-28 | Translate Bio Inc | Hírvivõ RNS tisztítására szolgáló eljárások |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| IL269458B2 (en) | 2017-03-23 | 2024-02-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| US20190300856A1 (en) * | 2017-08-16 | 2019-10-03 | Georgia Tech Research Corporation | Messenger RNA based expression of opsins and reporter proteins for electrophysiologic characterization of in vitro neurons and cardiomyocytes |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| AU2018352592C1 (en) | 2017-10-16 | 2025-09-25 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND PROCEDURES FOR PREDICTING REPAIR RESULTS IN GENE ENGINEERING |
| US20210000879A1 (en) * | 2018-03-01 | 2021-01-07 | Georgia Tech Research Corporation | Methods and compositions for mrna-based modulation and detection of cell phenotypes |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
| AU2019285719B2 (en) | 2018-06-11 | 2021-03-25 | The Regents Of The University Of California | Demethylation to treat eye disease |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| GB2592504B (en) | 2018-09-04 | 2023-02-15 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
| JP7425066B2 (ja) | 2018-09-04 | 2024-01-30 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 核酸を臓器特異的送達するための組成物および方法 |
| EP3853305B1 (en) | 2018-09-19 | 2024-10-02 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| WO2020061284A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| US11980673B2 (en) | 2018-10-09 | 2024-05-14 | The University Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| KR20210089648A (ko) | 2018-11-08 | 2021-07-16 | 트랜슬레이트 바이오 인코포레이티드 | 메신저 rna 정제를 위한 방법 및 조성물 |
| WO2020097511A2 (en) * | 2018-11-09 | 2020-05-14 | Translate Bio, Inc. | Messenger rna therapy for treatment of ocular diseases |
| AU2020206109B2 (en) | 2019-01-07 | 2024-12-19 | Translate Bio, Inc. | Composition and methods for treatment of primary ciliary dyskinesia |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3920950A1 (en) * | 2019-02-08 | 2021-12-15 | CureVac AG | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| GB2601618B (en) | 2019-03-19 | 2024-11-06 | Broad Inst Inc | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN118767255A (zh) | 2019-06-05 | 2024-10-15 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP2023546175A (ja) | 2020-10-14 | 2023-11-01 | ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド | 脂質ナノ粒子製造の方法及びそれに由来する組成物 |
| WO2022099003A1 (en) * | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| JP7817257B2 (ja) * | 2020-11-06 | 2026-02-18 | サノフィ パスツール インコーポレイテッド | ｍＲＮＡワクチンを送達するための脂質ナノ粒子 |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| US20240209068A1 (en) * | 2021-04-01 | 2024-06-27 | Modernatx, Inc. | Mucosal expression of antibody structures and isotypes by mrna |
| JP2024538489A (ja) | 2021-09-03 | 2024-10-23 | キュアバック エスイー | 核酸を送達するための新規な脂質ナノ粒子 |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US20260022386A1 (en) | 2021-11-01 | 2026-01-22 | Basecamp Research Ltd | Single Construct Platform for Simultaneous Delivery of Gene Editing Machinery and Nucleic Acid Cargo |
| WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
| WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
| WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| KR20250028547A (ko) | 2022-05-25 | 2025-02-28 | 큐어백 에스이 | 대장균 FimH 항원성 폴리펩타이드를 인코딩하는 핵산 기반 백신 |
| WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
| US12186389B2 (en) | 2022-10-28 | 2025-01-07 | Glaxosmithkline Biologicals Sa | Nucleic acid base vaccine against emerging SARS-CoV-2 variants |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2024138194A1 (en) | 2022-12-22 | 2024-06-27 | Tome Biosciences, Inc. | Platforms, compositions, and methods for in vivo programmable gene insertion |
| AU2024233180A1 (en) | 2023-03-08 | 2025-09-25 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| WO2024234006A1 (en) | 2023-05-11 | 2024-11-14 | Tome Biosciences, Inc. | Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs) |
| WO2025050069A1 (en) | 2023-09-01 | 2025-03-06 | Tome Biosciences, Inc. | Programmable gene insertion using engineered integration enzymes |
| WO2025224107A1 (en) | 2024-04-22 | 2025-10-30 | Basecamp Research Ltd | Method and compositions for detecting off-target editing |
| WO2025224182A2 (en) | 2024-04-23 | 2025-10-30 | Basecamp Research Ltd | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| EP1021549A2 (en) * | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
| US7507859B2 (en) * | 2003-06-16 | 2009-03-24 | Fifth Base Llc | Functional synthetic molecules and macromolecules for gene delivery |
| ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
| CA2604441A1 (en) * | 2005-04-12 | 2006-10-19 | Intradigm Corporation | Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
| CA2967156C (en) | 2005-04-18 | 2021-06-01 | Francine Behar-Cohen | Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject. |
| WO2008016473A2 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2008137066A1 (en) | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| EP2743265B1 (en) | 2008-10-09 | 2017-03-15 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| RS58405B1 (sr) * | 2009-12-01 | 2019-04-30 | Translate Bio Inc | Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima |
| US8889193B2 (en) | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| US9019345B2 (en) | 2010-07-02 | 2015-04-28 | Intuitive Surgical Operations, Inc. | Imaging mode blooming suppression |
| US8853377B2 (en) * | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| ES2385080B1 (es) | 2010-12-21 | 2013-05-10 | Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea | Nanopartículas lipídicas para el tratamiento de enfermedades oculares. |
| SMT201900445T1 (it) * | 2011-06-08 | 2019-09-09 | Translate Bio Inc | Composizione di nanoparticelle lipidiche e metodi per il rilascio di mrna |
| CA3198966A1 (en) | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Cleavable lipids |
| EA032088B1 (ru) | 2011-10-27 | 2019-04-30 | Массачусетс Инститьют Оф Текнолоджи | Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство |
| JP6149041B2 (ja) * | 2011-11-04 | 2017-06-14 | 日東電工株式会社 | 脂質−核酸粒子を無菌的に生成するための単回使用システム |
| RU2649364C2 (ru) * | 2011-12-16 | 2018-04-02 | Модерна Терапьютикс, Инк. | Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты |
| EP2607375A1 (en) | 2011-12-21 | 2013-06-26 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Variants of yeast NDI1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction. |
| BR112014024131A2 (pt) * | 2012-03-29 | 2017-07-25 | Shire Human Genetic Therapies | lipídios catiônicos ionizáveis |
| EP2830596B1 (en) * | 2012-03-29 | 2020-12-30 | Translate Bio, Inc. | Lipid-derived neutral nanoparticles |
| AU2013243954A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| CN105209490A (zh) * | 2013-03-14 | 2015-12-30 | 夏尔人类遗传性治疗公司 | 用于递送mrna编码的抗体的方法和组合物 |
| EA034103B1 (ru) * | 2013-10-22 | 2019-12-27 | Транслейт Био, Инк. | СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| JP6525435B2 (ja) * | 2013-10-22 | 2019-06-12 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | メッセンジャーｒｎａの送達のための脂質製剤 |
| EP3060303B1 (en) * | 2013-10-22 | 2018-11-14 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
-
2015
- 2015-03-19 RS RS20190099A patent/RS58337B1/sr unknown
- 2015-03-19 ES ES18201321T patent/ES2774552T3/es active Active
- 2015-03-19 PL PL15767977T patent/PL3122878T3/pl unknown
- 2015-03-19 US US15/128,303 patent/US20170143848A1/en not_active Abandoned
- 2015-03-19 EP EP19218561.9A patent/EP3699274A1/en active Pending
- 2015-03-19 WO PCT/US2015/021403 patent/WO2015148247A1/en not_active Ceased
- 2015-03-19 SM SM20190176T patent/SMT201900176T1/it unknown
- 2015-03-19 SI SI201530559T patent/SI3122878T1/sl unknown
- 2015-03-19 DK DK18201321.9T patent/DK3450553T3/da active
- 2015-03-19 HR HRP20190117TT patent/HRP20190117T1/hr unknown
- 2015-03-19 TR TR2019/00649T patent/TR201900649T4/tr unknown
- 2015-03-19 PT PT15767977T patent/PT3122878T/pt unknown
- 2015-03-19 ME MEP-2019-13A patent/ME03314B/me unknown
- 2015-03-19 DK DK15767977.0T patent/DK3122878T3/en active
- 2015-03-19 ES ES15767977T patent/ES2707969T3/es active Active
- 2015-03-19 HU HUE15767977A patent/HUE041940T2/hu unknown
- 2015-03-19 EP EP15767977.0A patent/EP3122878B1/en active Active
- 2015-03-19 LT LTEP15767977.0T patent/LT3122878T/lt unknown
- 2015-03-19 EP EP18201321.9A patent/EP3450553B1/en active Active
-
2019
- 2019-01-22 CY CY20191100085T patent/CY1121348T1/el unknown
-
2022
- 2022-02-03 US US17/592,335 patent/US20220354968A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT3122878T (lt) | 2019-02-11 |
| TR201900649T4 (tr) | 2019-02-21 |
| SI3122878T1 (sl) | 2019-05-31 |
| US20220354968A1 (en) | 2022-11-10 |
| EP3699274A1 (en) | 2020-08-26 |
| ME03314B (me) | 2019-10-20 |
| ES2707969T3 (es) | 2019-04-08 |
| RS58337B1 (sr) | 2019-03-29 |
| ES2774552T3 (es) | 2020-07-21 |
| EP3122878B1 (en) | 2018-10-24 |
| EP3122878A4 (en) | 2017-08-30 |
| EP3450553B1 (en) | 2019-12-25 |
| HRP20190117T1 (hr) | 2019-04-19 |
| DK3122878T3 (en) | 2019-02-04 |
| CY1121348T1 (el) | 2020-05-29 |
| PT3122878T (pt) | 2019-02-01 |
| DK3450553T3 (da) | 2020-02-10 |
| US20170143848A1 (en) | 2017-05-25 |
| EP3450553A1 (en) | 2019-03-06 |
| EP3122878A1 (en) | 2017-02-01 |
| WO2015148247A1 (en) | 2015-10-01 |
| SMT201900176T1 (it) | 2019-05-10 |
| HUE041940T2 (hu) | 2019-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3122878T3 (pl) | TERAPIA mRNA DO LECZENIA CHORÓB OCZU | |
| IL265497B (en) | Methods for treating eye diseases | |
| EP3212233A4 (en) | Combination therapy for treatment of disease | |
| IL248732A0 (en) | Compounds for the treatment of ophthalmological diseases and disorders | |
| IL253244B1 (en) | Methods for treating retinal diseases | |
| IL250960B (en) | Combined treatment of sinecriviroc for the treatment of leprosy | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| IL249502B (en) | New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins | |
| PL3210973T3 (pl) | Związki heteroarylowe do leczenia chorób oczu | |
| IL246721B (en) | History of 5-benzylisoquinoline for the treatment of cardiovascular diseases | |
| PL3129483T3 (pl) | Terapia skojarzona do leczenia chorób autoimmunologicznych | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| EP3340974A4 (en) | METHODS OF TREATING DISEASES | |
| EP3154637A4 (en) | Treatment of virus-based diseases of the skin | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| GB201517565D0 (en) | Treatment of genetic diseases | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases | |
| AU2014902075A0 (en) | New Therapeutic Treatment Combination |